Context Therapeutics (NASDAQ:CNTX) Releases Earnings Results, Misses Estimates By $0.06 EPS

Context Therapeutics (NASDAQ:CNTX) announced its quarterly earnings results on Wednesday. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.06), FiscalAI reports.

Context Therapeutics Trading Up 2.2%

Context Therapeutics stock traded up $0.01 during mid-day trading on Friday, hitting $0.52. 1,035,577 shares of the company’s stock were exchanged, compared to its average volume of 1,825,498. The stock has a market cap of $47.32 million, a P/E ratio of -1.07 and a beta of 1.74. The stock has a 50 day moving average of $0.91 and a two-hundred day moving average of $1.92. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.62.

Institutional Investors Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CNTX. Millennium Management LLC bought a new position in Context Therapeutics during the fourth quarter worth about $3,824,000. Marshall Wace LLP grew its stake in shares of Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares during the period. Vanguard Group Inc. grew its position in shares of Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after buying an additional 134,449 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Context Therapeutics in the 3rd quarter valued at $100,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on CNTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Maxim Group dropped their price target on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Finally, Citigroup reissued an “outperform” rating on shares of Context Therapeutics in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Context Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $6.17.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.